Is selective laser trabeculoplasty shifting the glaucoma treatment paradigm in developing countries?

In 2019, the Laser in Glaucoma and Ocular Hypertension (LiGHT) randomised controlled trial reported that initial treatment with selective laser trabeculoplasty (SLT) is more cost effective than initial treatment with pressure-lowering eye drops, leading to a reduced number of glaucoma surgeries and very low rates of adverse events while providing drop-free intraocular pressure (IOP) control to 78% of treated eyes after 3 years.1 2 As a result, the European Glaucoma Society,3 the American Academy of Ophthalmology4 and the UK National Institute for Health and Care Excellence5 now recommend the use of SLT as initial treatment for open-angle glaucoma (OAG) and ocular hypertension (OHT). Although the LiGHT trial provided evidence for change in the treatment of for mild and moderate OAG and OHT, the evidence for the management of advanced glaucoma is not as clear. There is still a lack...
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Open access Editorials Source Type: research